Crystec shortlisted for 2020 CPhI Excellence in Pharma Awards: Innovation in Response to COVID-19
Crystec are delighted to have been selected as a finalist for the 2020 CPhI Excellence in Pharma Awards in the category of Innovation in Response to COVID-19.
Crystec are involved in a number of COVID-19 programmes, focused on generating Dry Powder Inhaler (DPI) formulations of both small and large molecule therapeutics. Compared to nebulisation, DPI delivery can enable higher levels of lung deposition, and potentially reduce SARS-Cov-2 transmission risks associated with droplet formation. Using the unique capabilities of Crystec's mSAS® platform, the company are facilitating rapid development of optimised DPI therapies, accelerating the transition to clinical manufacture at commercial scale.
Shortlisted companies participated in an 'Innovation Pitch' during CPhI Festival of Pharma on Monday 12th October and the winners were announced at the Virtual CPhI Pharma Awards on Tuesday 13th October. Crystec's CPhI Awards pitch is available to view here!
To find out more about the awards, and for a full list of finalists and winners, click here.
If you would like to hear more about Crystec’s mSAS® technology and how it can be applied to develop optimised DPI products, please get in touch!